The Sami-Group’s Hyderabad facility, located in the Genome Valley, Hyderabad, India, is now GMP certified by NSF International.
This third-party registration confirms the facility is in compliance with good manufacturing practices.
The state-of-the-art production centre is situated in a 4.5 acre plot, houses facilities for herbal extractions and nutraceutical preparations.
The reactors are of varying capacities, ranging from 500–8000 L, with all distillation assembly and other requirements.
The factory is also equipped with an efficient quality control and microbiology lab that is capable of analysing all incoming and outgoing materials on a regular basis.
The top products from the Hyderabad unit are Sabinsa’s PteroWhite (Pterocarpus extract 90%), BioPerine (Black pepper 95%), Curcumin C3 Complex 95%, Boswellin and FenuFibers, which are supplied to several world markets.
The total output of this unit is 15-20 tonnes of some of the company’s key manufactured ingredients on a monthly basis. An additional 5 acre plot is available for future expansion needs.
“This third-party inspection and subsequent certification provides our customers with assurance that the products we manufacture will support their own regulatory compliance and quality standards,” said Shaheen Majeed, Sabinsa President, Worldwide.
“While we encourage our customers to visit us and conduct site inspections themselves, we also know that isn’t always possible. This location previously passed inspection by the US FDA, but we are pleased by this most recent confirmation of our manufacturing standards as well. This marks the third Sabinsa factory to be NSF GMP certified.”
The Genome Valley is India’s largest concentration of systematically developed R&D facilities, boasting world-class infrastructure in the form of Industrial and Research Parks, Special Economic Zones (SEZs), and multi-tenant wet laboratories and incubation facilities.
The cluster synergises a healthy mix of companies in the realm of agri-biotech, clinical research management (CRM), biopharma, vaccine manufacturing, regulatory and testing and other related areas.